Form 4: Amylyx Pharmaceuticals Chief Legal Officer Sells Shares to Cover Tax Obligations

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 3,678 shares of common stock on February 3, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Gina Mazzariello, the Chief Legal Officer of Amylyx Pharmaceuticals, sold 3,678 shares of common stock on February 3, 2025.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $3.4908, with individual transactions ranging from $3.46 to $3.56.
• Following the transaction, Mazzariello directly owns 139,090 shares of Amylyx Pharmaceuticals.
• The sale was automatic and not at the discretion of the reporting person.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine transaction to cover tax obligations, not indicative of a significant change in the officer's view of the company.

Industry Context

This is a routine Form 4 filing, which is common for corporate officers who sell shares to cover tax obligations related to stock-based compensation. It doesn't necessarily reflect a change in the officer's outlook on the company.

Stakeholder Impact

• The sale of shares could have a minor, temporary impact on the stock price, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Amylyx Pharmaceuticals, Gina Mazzariello, insider trading, Form 4, stock sale, tax withholding, restricted stock units, AMLX